Canada-based OncoGenex Pharmaceuticals (Nasdaq: OGXI) saw its shares rise 0.9% to $2.19 on Tuesday, despite announcing that Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) is returning rights to custirsen, an investigational compound currently being evaluated in Phase III clinical development as a treatment for prostate and lung cancers.
This transfer of rights would occur in connection with the termination of the collaboration agreement between OncoGenex and Teva executed in 2009, which was worth a potential $440 million to OncoGenex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze